Kleinostheim, Germany, 4th
October 2010 - curasan AG, listed in the General Standard (ISIN: DE 000
549 453 8) expects to make a considerable profit instead of the two
million euro loss announced for the financial year 2010.
The reason for this is the contract agreement that has just been concluded for the sale of the oncological product Mitem®
to the Speciality European Pharma Ltd. (SEP), London, and the
extraordinary earnings associated with it. The sale will tentatively
come into effect on 1st November.
It has been agreed to maintain silence regarding the value of the transaction.
AG, thus, finalizes the concentration of the product portfolio in the
biomaterials sector with the sale of the pharmaceutical drug Mitem®. The liquidity position of the company, which is very good anyway, will improve considerably as a result of this development.
Background information about curasan AG:
listed curasan AG (ISIN: DE 000 549 453 8) is one of the leading firms
in the field of regenerative medicine especially in bone and tissue
regeneration. In addition to the synthetic Cerasorb® bone
substitution and regeneration material, the company has developed a
future-oriented product pipeline. The goal during the next few years is
to have further medical products ready for market rollout via
well-positioned contractual partners in various market segments.
About Speciality European Pharma Ltd:
in April 2006, SEP is a privately owned speciality pharmaceutical
company. Its mission is to become the leading urology-focused speciality
pharmaceutical business in Europe. SEP owns worldwide rights to
PLENAXIS®. SEP has distribution rights in a number of European countries for Haemopressin®/Variquel®,
a product for the treatment of Bleeding Oesophageal Varices. In the UK
and Ireland, SEP also has the distribution rights to Regurin® for the treatment of overactive bladder. The new once daily formulation, Regurin® XL, was launched in September 2009.
has established its own commercial operations in the UK, Germany,
France and Italy and will market its products in other regions and
territories through relationships with expert partners.
To learn more about Speciality European Pharma, please visit www.specialityeuropeanpharma.com
Tel. +49 (0)6027 40 900-51
Fax +49 (0)6027 40 900-39
fr financial relations gmbh
Tel. +49 (0)69 95 90 83 20
Fax +49 (0)69 95 90 83 99
Last Updated on Sunday, 07 November 2010 00:25
OrthopaedicsOne is a collaborative orthopaedic knowledge network. Contribute to orthopaedics and orthopaedic surgery knowledge.
Orthopaedic Web Links -
Comprehensive directory of orthopedics, orthopedic surgery & trauma. Search for orthopaedic surgeons, implants, equipment and resources on back pain, broken bones, other orthopaedic conditions.
Find a physiotherapy clinic in Canada with MyPhysiotherapy.ca. Simple. Quick. Effective.
OrthoZilla is a comprehensive, easy to use orthopedics & orthopedic surgery products search engine.
This site complies with the HONcode standard for trustworthy health information: verify here.
© 1999-2012 Orthogate